在心力衰竭中,神经质机制是基于性别的对心肺呼吸系统功能障碍的基础
Katherin Pereyra1, Karla G Schwarz1, Esteban Díaz-Jara1
1Laboratory of Cardiorespiratory Control, Department of Physiology, Pontificia Universidad Católica de Chile, Santiago, Chile.
Clinical science (London, England : 1979)
|December 23, 2025
概括
患有慢性心力衰竭 (CHF) 的雄性大鼠由于RVLM C1神经元过活和质细胞变化而出现严重的心脏呼吸系统问题. 患有CHF的雌性大鼠对这些神经生理变化表现出保护,导致症状较轻微.
科学领域:
- 心血管科学 心血管科学
- 神经科学是一个神经科学.
- 生理学 生理学 生理学
背景情况:
- 慢性心力衰竭 (CHF) 呈现出显著的发病率和死亡率,通常涉及心肺呼吸系统疾病,如同情感兴奋和呼吸障碍.
- 之前的研究表明,在CHF大鼠中,RVLM神经元过度活跃,导致心肺呼吸系统不良.
- 在CHF病理生理学上的性别差异,特别是关于RVLM中保存的喷射分数和神经生理学重塑,仍然不清楚.
研究的目的:
- 调查基于性别的心脏功能,自主/呼吸控制和RVLM C1神经元/质细胞激活的性别差异,在体积过载引起的CHF的老鼠模型中.
- 为了确定RVLM中的神经生理重塑是否在CHF诱导后的雄性和雌性大鼠之间有所不同.
主要方法:
- 成年雄性和雌性Sprague-Dawley大鼠经历了实验性诱导的体积过载CHF.
- 心脏功能 (心和腹),自主/呼吸参数以及RVLM C1神经元和天体细胞激活在心衰竭后8周被评估.
- 组织学分析检查了RVLM内的天体细胞反应性和复杂性.
主要成果:
- 与雌性CHF大鼠相比,雄性CHF大鼠表现出较大的左心室扩张,抑郁的心脏功能,心肌细胞处理受损,以及显著的心脏节律失调,同情激发和呼吸障碍.
- 在雄性CHF大鼠中,RVLM C1神经元长期活跃,但在雌性CHF大鼠中没有.
- 雄性CHF大鼠在RVLM中表现出星细胞反应性和星细胞复杂性的增加,而雌性CHF大鼠则没有这种复杂性.
结论:
- 与雄性大鼠相比,在体积过载的CHF中,淋巴管完整的雌性大鼠表现出对RVLM天体细胞重塑和慢性C1神经元激活的保护.
- 这些取决于性别的神经生理学差异有助于在患有慢性心力衰竭的雌性大鼠中减轻严重的心肺病理.
- 这些发现突出了神经心肺呼吸系统对心脏不全症反应的关键性别差异,表明了潜在的治疗点.
相关概念视频
Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
Pathophysiology of Cardiac Performance
1.3K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
Psychoneuroimmunology: Cardiovascular Disease
363
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
363
Heart Failure I: Introduction
653
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
653


